These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Author: Molina M, Navarro MJ, de Gracia C, Alvarez G, de Alarcon R, Garcia MA.
    Journal: Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951.
    Abstract:
    One hundred and four patients receiving hemodialysis and undergoing anaemia treatment with darbepoetin alfa intravenously once weekly were switched to a biweekly dosing schedule and followed for 24 weeks. The darbepoetin alfa dose was adjusted to maintain the target Hb concentration of 11-14 g/dL. A significant decline in the erythropoiesis-stimulating agent resistance index was observed over the 24-week follow-up, beginning with week 16, whereas the mean dose of darbepoetin alfa did not change significantly after switching to the biweekly dosing schedule. Other factors that might affect resistance to erythropoiesis remained unchanged.
    [Abstract] [Full Text] [Related] [New Search]